The biotech industry is heating up with a groundbreaking anticoagulation drug being developed by Ionis (IONS).
For successful conventional or online stock trading, it is important to check out any groundbreaking product that a company could be bringing out. That could significantly raise its stock value, making it easier for you to decide if you need to buy that stock.
In the biotech industry Ionis Pharmaceuticals (IONS) has a major ace up its sleeve, in the form of a drug that makes use of its RNA antisense technology. It’s the anticoagulant drug of the company that could give it the market dominance it craves for.
That drug that’s raising investor hopes is the IONIS-FXIRx, that’s pronounced “Factor 11 Rx”. This blood clot prevention drug takes an unconventional approach. It inhibits Factor XI production by the liver. Here’s an explanation of how this mechanism works.
Inhibiting Factor Xl Production
Factor XI, produced by the liver, facilitates blood coagulation or clotting. This is an essential characteristic of blood. Failure to clot leads to excessive blood loss when an injury strikes. However, unnecessary and excessive clotting of blood could cause stroke and heart attack. This is caused by the liver producing excessive Factor XI. Deficiency of Factor XI leads to lesser occurrences of blood clot formation though amazingly it does not simultaneously result in increasing the risk of bleeding. Inhibiting Factor XI production can prevent clotting without other side effects.
Conventional blood anticoagulant drugs, though, work in a different manner and come with increased bleeding risk. If released in the market, IONIS-FXIRx will be the first thrombosis (blood clot) reducing drug that does not increase the risk of bleeding. That gives this drug a significant advantage over the other more conventional anticoagulant drugs, and has phenomenal scope for use in healthcare.
Trial Results Confirm Advantages
These theoretical advantages of this anticoagulant drug have also been proven so far in trial results. A study in phase 2 involving 293 patients who underwent total knee replacement revealed that venous thromboembolic events in patients on IONIS-FXIRx reduced seven-fold without any increased bleeding. Another study conducted on severe kidney disease patients on dialysis also revealed a reduction in the number of severe clotting events with no adverse treatment-related side effects.
And now Bayer AG is helping Ionis develop this drug further for which Bayer has provided $75 million to Ionis. Bayer will also be funding the development of the second Factor XI drug that is being developed on the Ligand Conjugated Antisense (LICA) chemical modification. The LICA modification enables the drug to be targeted to specific tissues. This enables the drug to be delivered in a more powerful and effective manner but in smaller doses.
This is certainly great news for biotech investors. It presents a new opportunity since the safety and effectiveness of IONIS-FXIRx makes it applicable to multiple diseases. Currently, Ionis’ stock price is 28% below the all-time high. If the Factor XI drugs begin displaying their advantages in various healthcare settings once they’re released in the market, the stock value could soar.